ATX-101
Ovarian Cancer
Key Facts
About APIM Therapeutics
APIM Therapeutics is a Norwegian biotech company pioneering a novel approach to cancer therapy by targeting the proliferating cell nuclear antigen (PCNA) and its interaction with the AlkB homologue 2 PCNA interacting motif (APIM). Its lead clinical asset, ATX-101, is a first-in-class peptide that has progressed to Phase Ib trials in ovarian cancer and Phase II trials in sarcoma, aiming to overcome treatment resistance. The company is building a pipeline of peptide drugs focused on disrupting cancer cell survival mechanisms under therapeutic stress. Leveraging its academic roots from NTNU, APIM seeks to develop both single-agent and combination therapies for unmet needs in oncology.
View full company profileAbout APIM Therapeutics
APIM Therapeutics is a Norwegian biotech company pioneering a novel approach to cancer therapy by targeting the proliferating cell nuclear antigen (PCNA) and its interaction with the AlkB homologue 2 PCNA interacting motif (APIM). Its lead clinical asset, ATX-101, is a first-in-class peptide that has progressed to Phase Ib trials in ovarian cancer and Phase II trials in sarcoma, aiming to overcome treatment resistance. The company is building a pipeline of peptide drugs focused on disrupting cancer cell survival mechanisms under therapeutic stress. Leveraging its academic roots from NTNU, APIM seeks to develop both single-agent and combination therapies for unmet needs in oncology.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| Platform Candidate | FLAG Therapeutics | Preclinical |